0G8X.LSE Immunovia AB
- Market cap
- SEK 3.86M
- P/E
- -
- P/B
- -
- ROE
- -349.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0G8X.LSE undervalued?
Graham numberThe Graham number of Immunovia AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Immunovia AB fundamental analysis
No fundamental analysis for Immunovia AB yet.
Immunovia AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Immunovia AB
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Full company profileImmunovia AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Immunovia AB annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 24.5M | 24.2M | 333K | 356K | 362K | 844K | 1.15M | 1.58M | 931K | 685K | 1.51M |
| Gross Profit | 1.28M | -13.4M | -39.9M | -114M | -134M | -165M | -191M | -295M | -107M | -79.5M | -81.1M |
| Operating Income | -15.0M | -45.6M | -88.2M | -114M | -134M | -165M | -191M | -297M | -107M | -79.5M | -81.1M |
| EBITDA | -14.4M | -44.0M | -83.8M | -105M | -135M | -135M | -142M | -167M | -61.3M | -77.2M | -79.6M |
| Net Income | -14.7M | -45.2M | -86.5M | -115M | -146M | -156M | -168M | -309M | -76.5M | -146M | -82.5M |
| EPS | -0.98 | -2.67 | -4.67 | -5.43 | -6.35 | -6.40 | -6.89 | -7.95 | -0.93 | -0.42 | -0.12 |
| Balance Sheet | |||||||||||
| Total Assets | 283M | 251M | 477M | 419M | 661M | 494M | 301M | 98.7M | 33.0M | 88.2M | 48.0M |
| Total Liabilities | 6.78M | 14.0M | 15.4M | 61.8M | 61.8M | 59.9M | 56.8M | 31.7M | 21.4M | 23.5M | 24.4M |
| Shareholders' Equity | 277M | 237M | 462M | 358M | 599M | 434M | 244M | 67.0M | 11.6M | 64.7M | 23.6M |
| Cash & Short-term Investments | 259M | 192M | 386M | 263M | 468M | 287M | 106M | 76.8M | 25.3M | 77.5M | 34.9M |
| Total Debt | - | - | - | 38.1M | 33.1M | 33.3M | 37.6M | 4.29M | 680K | 857K | 3.27M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -11.9M | -46.3M | -84.1M | -92.0M | -121M | -153M | -176M | -147M | -96.8M | -78.4M | -82.9M |
| Capital Expenditure | 2.78M | 5.37M | 9.06M | 36.6M | 47.5M | 24.2M | 1.62M | 1.06M | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -14.6M | -51.7M | -93.2M | -129M | -168M | -177M | -177M | -148M | -96.8M | -78.4M | -82.9M |
| Ratios | |||||||||||
| ROE | -5.3% | -19.1% | -18.7% | -32.0% | -24.4% | -35.9% | -68.9% | -461.9% | -657.1% | -225.4% | -349.2% |
| ROA | -5.2% | -18.0% | -18.1% | -27.3% | -22.1% | -31.6% | -55.9% | -313.6% | -231.6% | -165.4% | -171.8% |
| Net Profit Margin | -60.1% | -187.0% | -25,987.7% | -32,168.8% | -40,340.6% | -18,479.4% | -14,680.5% | -19,646.9% | -8,221.4% | -21,301.5% | -5,465.3% |
| Debt to Equity | - | - | - | 0.11x | 0.06x | 0.08x | 0.15x | 0.06x | 0.06x | 0.01x | 0.14x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Immunovia AB dividends
Immunovia AB has not paid dividends in the last 9 fiscal years.
Last stock split: 463:360 on Oct 2, 2025.
Who owns Immunovia AB
- Insiders 9.77%
- Institutions 16.53%
- Public & others 73.69%
- Shares outstanding 19.5M
- Free float 620M
Immunovia AB company profile
- Company name
- Immunovia AB
- Ticker
- 0G8X.LSE
- ISIN
- SE0006091997
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 18
- Fiscal year end
- December
- Address
- Medicon Village, Lund, Sweden, 223 63
- Phone
- 46 4 62 75 60 00
- Website
- immunovia.com
About Immunovia AB
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Immunovia AB management
2- Mr. Jeff BorcherdingGlobal Chief Executive Officer & President · born 1973
- Ms. Sarah DeDiemarVP of Sales & Marketing